Maria Dolores Cayero-Otero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Maria Dolores Cayero-Otero has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Lucía Martín-Banderas
Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia Universidad de Sevilla Sevilla Spain
2 shared publications - Ahmet Alper Öztürk
Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Türkiye
1 shared publication Ana M. Espinosa-Oliva
Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de Sevilla, and Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain
1 shared publicationAntonio J. Herrera
Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de Sevilla, and Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain
1 shared publicationBehiye Şenel
1 shared publication- Bruno Sarmento
Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal; Instituto Universitário de Ciências da Saúde (IUCS-CESPU), Rua Central de Gandra 1317, 4585-116 Gandra, Portugal
1 shared publication
Latest Publications
- 1 January 2024
- Published by Editorial Universidad de Sevilla
- p. 469-481
Resolución de casos reales en las oficinas de farmacia de la provincia de Sevilla. Ciclo de mejora en el aula de Legislación, Gestión y Planificación Farmacéutica
Este trabajo incluye el desarrollo y los resultados que se han obtenido tras la aplicación de un Ciclo de Mejora en el Aula (CIMA) en la asignatura obligatoria Legislación, Gestión y Planificación Farmacéutica del 4º curso del Grado en Farmacia (curso 2023-2024). La temática principal de las prácticas es que los alumnos conozcan la legislación vigente y el funcionamiento básico de una oficina de farmacia (OF) ya que, en meses venideros, se enfrentarán a sus prácticas tuteladas. Por lo tanto, el principal objetivo del presente CIMA es la integración de los alumnos en situaciones reales de casos extraídos de diferentes OF de la provincia de Sevilla a través de un role-play donde actuarán como pacientes o farmacéuticos. Los alumnos han mostrado gran interés en este tipo de aprendizaje, obteniéndose resultados que ponen de manifiesto la utilidad práctica del CIMA para que los alumnos aprendan y sean capaces de desarrollar lo aprendido. Así mismo, ellos se sienten más motivados e integrados con la asignatura, sintiéndose como auténticos profesionales.
- 1 January 2024
- Published by Editorial Universidad de Sevilla
- p. 469-481
Resolución de casos reales en las oficinas de farmacia de la provincia de Sevilla. Ciclo de mejora en el aula de Legislación, Gestión y Planificación Farmacéutica
Este trabajo incluye el desarrollo y los resultados que se han obtenido tras la aplicación de un Ciclo de Mejora en el Aula (CIMA) en la asignatura obligatoria Legislación, Gestión y Planificación Farmacéutica del 4º curso del Grado en Farmacia (curso 2023-2024). La temática principal de las prácticas es que los alumnos conozcan la legislación vigente y el funcionamiento básico de una oficina de farmacia (OF) ya que, en meses venideros, se enfrentarán a sus prácticas tuteladas. Por lo tanto, el principal objetivo del presente CIMA es la integración de los alumnos en situaciones reales de casos extraídos de diferentes OF de la provincia de Sevilla a través de un role-play donde actuarán como pacientes o farmacéuticos. Los alumnos han mostrado gran interés en este tipo de aprendizaje, obteniéndose resultados que ponen de manifiesto la utilidad práctica del CIMA para que los alumnos aprendan y sean capaces de desarrollar lo aprendido. Así mismo, ellos se sienten más motivados e integrados con la asignatura, sintiéndose como auténticos profesionales.
- 2 December 2019
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 16 (12) , 1413-1427
In vivo biodistribution of venlafaxine-PLGA nanoparticles for brain delivery: plain vs. functionalized nanoparticles
Background: Actually, no drugs provide therapeutic benefit to approximately one third of depressed patients. Depression is predicted to become the first global disease by 2030. So, new therapeutic interventions are imperative. Research design and methods: Venlafaxine loaded-poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) were surface functionalized with two ligands against transferrin receptor to enhance access to brain. An in vitro blood-brain barrier model using hCMEC/D3 cell line was developed to evaluate permeability. In vivo biodistribution studies were performed using C57/bl6 mice. Particles were administered intranasal and main organs were analyzed. Results: Particles were obtained as a lyophilized powder easily to re-suspend. Internalization and permeability studies showed the following cell association sequence: TfRp-NPs>Tf-NPs>plain NPs. Permeability studies also showed that encapsulated VLF was not affected by P-gP pump efflux increasing its concentration in the basolateral side after 24h. In vivo studies showed that 25% of plain NPs reach the brain after 30 min of one intranasal administration while less than 5% of functionalized NPs get the target. Conclusions:Plain NPs showed the highest ability to reach the brain vs functionalized NPs after 30 min by intranasal administration. We suggest plain NPs probably travel via direct nose-to-brian route whereas functionalized NPs reach the brain by receptor-mediated endocytosis.
- 2 December 2019
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 16 (12) , 1413-1427
In vivo biodistribution of venlafaxine-PLGA nanoparticles for brain delivery: plain vs. functionalized nanoparticles
Background: Actually, no drugs provide therapeutic benefit to approximately one third of depressed patients. Depression is predicted to become the first global disease by 2030. So, new therapeutic interventions are imperative. Research design and methods: Venlafaxine loaded-poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) were surface functionalized with two ligands against transferrin receptor to enhance access to brain. An in vitro blood-brain barrier model using hCMEC/D3 cell line was developed to evaluate permeability. In vivo biodistribution studies were performed using C57/bl6 mice. Particles were administered intranasal and main organs were analyzed. Results: Particles were obtained as a lyophilized powder easily to re-suspend. Internalization and permeability studies showed the following cell association sequence: TfRp-NPs>Tf-NPs>plain NPs. Permeability studies also showed that encapsulated VLF was not affected by P-gP pump efflux increasing its concentration in the basolateral side after 24h. In vivo studies showed that 25% of plain NPs reach the brain after 30 min of one intranasal administration while less than 5% of functionalized NPs get the target. Conclusions:Plain NPs showed the highest ability to reach the brain vs functionalized NPs after 30 min by intranasal administration. We suggest plain NPs probably travel via direct nose-to-brian route whereas functionalized NPs reach the brain by receptor-mediated endocytosis.
- 1 March 2019
- Published by Elsevier in Pharmacological Research
- Vol. 141, 451-465
A novel nanoformulation of PLGA with high non-ionic surfactant content improves in vitro and in vivo PTX activity against lung cancer
- 1 March 2019
- Published by Elsevier in Pharmacological Research
- Vol. 141, 451-465
A novel nanoformulation of PLGA with high non-ionic surfactant content improves in vitro and in vivo PTX activity against lung cancer
- Open Access
- 13 February 2019
- Published by African Journals Online (AJOL) in Tropical Journal of Pharmaceutical Research
- Vol. 18 (1) , 1-11-11
Dexketoprofen trometamol-loaded poly-lactic-co-glycolic acid (PLGA) nanoparticles: Preparation, in vitro characterization and cyctotoxity
Dexketoprofen trometamol-loaded poly-lactic-co-glycolic acid (PLGA) nanoparticles: Preparation, in vitro characterization and cyctotoxity
- 13 February 2019
- Published by African Journals Online (AJOL) in Tropical Journal of Pharmaceutical Research
- Vol. 18 (1) , 1-11-11
Open AccessDexketoprofen trometamol-loaded poly-lactic-co-glycolic acid (PLGA) nanoparticles: Preparation, in vitro characterization and cyctotoxity
Dexketoprofen trometamol-loaded poly-lactic-co-glycolic acid (PLGA) nanoparticles: Preparation, in vitro characterization and cyctotoxity
- 13 July 2018
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 24 (14) , 1589-1616
Potential Use of Nanomedicine for the Anti-inflammatory Treatment of Neurodegenerative Diseases
Neurodegenerative diseases, like Alzheimer´s and Parkinson´s disease, are a group of disorders that have in common their increasingly high prevalence along with the shortage of effective treatments. In addition, the scientific community faces the challenge of getting the drugs used in these treatments to cross the blood-brain barrier (BBB) and reach the brain in sufficient concentration to be able to exert its effect. Hence, researchers across multiple disciplines are working together in order to improve the ability of therapeutics to penetrate the BBB. In this sense, the use of nanomedicine, nanoscale structures for drug delivery, exhibits a really high therapeutic potential in the field of neurodegenerative diseases therapy. Since there is new evidence that neuroinflammation produced by reactive microglia contributes to the activation and pathogenesis of neurological disorders, many investigations focus on the identification of new targets whose inhibition can reduce, totally or partially, microglial activation. This review analyzes a wide variety of compounds as possible candidates to achieve this target, from compounds with a natural origin to anti-diabetics, antidepressants, antibiotics and hormones. We also discuss the different strategies to enhance the capacity of these compounds to cross the BBB. Although this review focuses on PLGA nanoparticles as one of the most versatile drug delivery nanosystems, we also describe other strategies, such as direct intranasal administration (nose-tobrain), novel viral vectors and novel implanted catheters.
- 13 July 2018
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 24 (14) , 1589-1616
Potential Use of Nanomedicine for the Anti-inflammatory Treatment of Neurodegenerative Diseases
Neurodegenerative diseases, like Alzheimer´s and Parkinson´s disease, are a group of disorders that have in common their increasingly high prevalence along with the shortage of effective treatments. In addition, the scientific community faces the challenge of getting the drugs used in these treatments to cross the blood-brain barrier (BBB) and reach the brain in sufficient concentration to be able to exert its effect. Hence, researchers across multiple disciplines are working together in order to improve the ability of therapeutics to penetrate the BBB. In this sense, the use of nanomedicine, nanoscale structures for drug delivery, exhibits a really high therapeutic potential in the field of neurodegenerative diseases therapy. Since there is new evidence that neuroinflammation produced by reactive microglia contributes to the activation and pathogenesis of neurological disorders, many investigations focus on the identification of new targets whose inhibition can reduce, totally or partially, microglial activation. This review analyzes a wide variety of compounds as possible candidates to achieve this target, from compounds with a natural origin to anti-diabetics, antidepressants, antibiotics and hormones. We also discuss the different strategies to enhance the capacity of these compounds to cross the BBB. Although this review focuses on PLGA nanoparticles as one of the most versatile drug delivery nanosystems, we also describe other strategies, such as direct intranasal administration (nose-tobrain), novel viral vectors and novel implanted catheters.